Printer Friendly

Pfizer ends plans to market over-the-counter version of Lipitor in US.

M2 PHARMA-July 30, 2015-Pfizer ends plans to market over-the-counter version of Lipitor in US

(C)2015 M2 COMMUNICATIONS

Pfizer, a United States-based drug manufacturer, has ended its plan to market an over-the-counter version of its cholesterol pill, Lipitor, in the United States, it was reported yesterday.

During December 2014, the firm completed a Phase III actual use trial, which was intended to simulate the OTC use of Lipitor (atorvastatin calcium) 10mg.

The program was ended as the trial did not meet its primary objectives of indicating patient compliance with the direction to check their low-density lipoprotein cholesterol (LDL-C) level and, after checking their LDL-C level, took appropriate action based on their test results.

Initiated in October 2013, the Phase III actual use trial enrolled around 1,311 patients.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 30, 2015
Words:139
Previous Article:OncoMed Pharmaceuticals commences Phase Ia/Ib clinical trial of anti-RSPO3 antibody.
Next Article:Boehringer Ingelheim signs exclusive license and collaboration agreement with Hanmi Pharmaceutical.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |